European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
SAN DIEGO, August 24, 2026–(BUSINESS WIRE)–Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European …
#Europe #EU #ACADIAPharmaceuticals #DAYBU #EuropeanCommission #EuropeanUnion #neurodevelopmentaldisorder #pediatricpatients #raredisease #Rettsyndrome #treatmentoption #treatmentoptions
https://www.europesays.com/europe/122619/